共 235 条
[1]
Weber M(2009)Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension? J Hypertens Suppl 27 S9-S14
[2]
Hoogwerf BJ(2010)Renin-angiotensin system blockade and cardiovascular and renal protection Am J Cardiol 105 30A-35A
[3]
Ong HT(2009)Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection? J Am Board Fam Med 22 686-697
[4]
Khan NA(2009)The 2009 Canadian hypertension education program recommendations for the management of hypertension: part 2—therapy Can J Cardiol 25 287-298
[5]
Hemmelgarn B(2009)Latin American guidelines on hypertension. Latin American expert group J Hypertens 27 905-922
[6]
Herman RJ(2008)Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association professional education committee of the Council for High Blood Pressure Research Circulation 117 e510-e526
[7]
Bell CM(1997)Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade Pharmacology 55 244-251
[8]
Mahon JL(2002)Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension Kidney Int 61 1462-1468
[9]
Leiter LA(2004)Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study Hypertens Res Off J Jpn Soc Hypertens 27 457-453
[10]
Rabkin SW(1999)Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension Clin Ther 21 442-12